Company announcements · 19/10/2026

Protego announces FDA IND clearance for Phase 2/3 study of PROT-001 in AL Amyloidosis

- Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis - Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma...